CL2015003569A1 - “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct - Google Patents
“compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pctInfo
- Publication number
- CL2015003569A1 CL2015003569A1 CL2015003569A CL2015003569A CL2015003569A1 CL 2015003569 A1 CL2015003569 A1 CL 2015003569A1 CL 2015003569 A CL2015003569 A CL 2015003569A CL 2015003569 A CL2015003569 A CL 2015003569A CL 2015003569 A1 CL2015003569 A1 CL 2015003569A1
- Authority
- CL
- Chile
- Prior art keywords
- phenyl
- heterocyclyl
- aryl
- dioxan
- piperazin
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 title 2
- 125000000217 alkyl group Chemical group 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE (ARIL Ó HETEROARIL)METIL-2-(ARIL, HETEROCICLIL, CICLOALQUIL Ó ALQUIL)-1,3-DIOXAN-METOXI-FENIL-PIPERAZIN-1-IL-FENIL-HETEROCICLIL SUSTITUIDO, A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DE LA FIBROSIS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361832768P | 2013-06-07 | 2013-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003569A1 true CL2015003569A1 (es) | 2016-11-11 |
Family
ID=52008597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003569A CL2015003569A1 (es) | 2013-06-07 | 2015-12-07 | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct |
Country Status (20)
Country | Link |
---|---|
US (2) | US9663499B2 (es) |
EP (2) | EP3626242A1 (es) |
JP (1) | JP6414831B2 (es) |
KR (1) | KR102240329B1 (es) |
CN (1) | CN105392364B (es) |
AU (1) | AU2014274830B2 (es) |
BR (1) | BR112015030203A2 (es) |
CA (1) | CA2913634C (es) |
CL (1) | CL2015003569A1 (es) |
DK (1) | DK3003038T3 (es) |
EA (1) | EA201592157A1 (es) |
ES (1) | ES2755125T3 (es) |
HK (1) | HK1221606A1 (es) |
MX (1) | MX2015016783A (es) |
PE (1) | PE20160523A1 (es) |
PL (1) | PL3003038T3 (es) |
PT (1) | PT3003038T (es) |
SG (1) | SG11201510011VA (es) |
TN (1) | TN2015000519A1 (es) |
WO (1) | WO2014197738A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
EP3626242A1 (en) | 2013-06-07 | 2020-03-25 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
AU2015360583B2 (en) * | 2014-12-10 | 2020-01-23 | The Scripps Research Institute | Small molecule inhibitors of fibrosis |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
WO2017184586A1 (en) * | 2016-04-18 | 2017-10-26 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
US20190282565A1 (en) * | 2018-03-19 | 2019-09-19 | Gui-Bai Liang | Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis |
EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
EP3863723A4 (en) * | 2018-10-14 | 2022-09-07 | The University of Chicago | COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSION |
MX2022012487A (es) * | 2020-04-07 | 2023-02-09 | Amarin Pharmaceuticals Ie Ltd | Métodos para tratar y/o prevenir infecciones y/o enfermedades virales causadas por virus en un sujeto que lo necesita. |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4619931A (en) | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
IL103558A0 (en) | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
CN1041425C (zh) | 1993-11-19 | 1998-12-30 | 国际壳牌研究有限公司 | 氧化稳定的聚酮聚合物组合物及其应用 |
US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
US5625064A (en) | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
ATE253915T1 (de) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
NZ523443A (en) | 2000-06-20 | 2004-11-26 | Atherogenics Inc | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders |
EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
AU2008335880B2 (en) * | 2007-12-13 | 2014-03-13 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
EP2648726B1 (en) | 2010-12-07 | 2018-04-04 | Amira Pharmaceuticals, Inc. | Polycyclic lpa1 antagonist and uses thereof |
US9346791B2 (en) * | 2011-09-07 | 2016-05-24 | The Johns Hopkins University | Itraconazole analogs and use thereof |
EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
KR102292853B1 (ko) | 2013-06-07 | 2021-08-24 | 리젠 파마슈티컬스 소시에떼 아노님 | 이중 선택적 pi3 델타 및 감마 키나아제 억제제 |
EP3626242A1 (en) | 2013-06-07 | 2020-03-25 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
-
2014
- 2014-06-05 EP EP19191562.8A patent/EP3626242A1/en active Pending
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en active Application Filing
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active IP Right Grant
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2016
- 2016-08-20 HK HK16109962.7A patent/HK1221606A1/zh unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014274830A1 (en) | 2015-11-26 |
MX2015016783A (es) | 2016-07-18 |
SG11201510011VA (en) | 2016-01-28 |
EP3003038A1 (en) | 2016-04-13 |
KR20160029028A (ko) | 2016-03-14 |
JP2016521710A (ja) | 2016-07-25 |
ES2755125T3 (es) | 2020-04-21 |
US20170217943A1 (en) | 2017-08-03 |
CN105392364B (zh) | 2018-09-14 |
BR112015030203A2 (pt) | 2017-07-25 |
HK1221606A1 (zh) | 2017-06-09 |
EP3626242A1 (en) | 2020-03-25 |
US9663499B2 (en) | 2017-05-30 |
US9981956B2 (en) | 2018-05-29 |
TN2015000519A1 (en) | 2017-04-06 |
JP6414831B2 (ja) | 2018-10-31 |
PL3003038T3 (pl) | 2020-02-28 |
EP3003038B1 (en) | 2019-08-14 |
CA2913634A1 (en) | 2014-12-11 |
PE20160523A1 (es) | 2016-05-25 |
DK3003038T3 (da) | 2019-11-11 |
KR102240329B1 (ko) | 2021-04-14 |
WO2014197738A1 (en) | 2014-12-11 |
PT3003038T (pt) | 2019-11-19 |
AU2014274830B2 (en) | 2017-11-09 |
CN105392364A (zh) | 2016-03-09 |
EA201592157A1 (ru) | 2016-05-31 |
EP3003038A4 (en) | 2016-11-16 |
US20160130258A1 (en) | 2016-05-12 |
CA2913634C (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
CL2016001120A1 (es) | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct | |
CL2018003290A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
CL2015002860A1 (es) | Antagonistas de la alfa-v-beta-6 integrina | |
CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
CL2016001933A1 (es) | Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct | |
CL2017000654A1 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2016001364A1 (es) | Moduladores de ror gamma (rory) | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
CL2015003689A1 (es) | Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm. | |
CR20160419A (es) | Nuevos compuestos biciclicos | |
CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CR20160499A (es) | Composiciones estables de yodo no en complejo y métodos de uso | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
CL2015002060A1 (es) | Compuestos. | |
CL2016003023A1 (es) | “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct | |
DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral |